Let’s K-Talk: A Storytelling Intervention Leveraging Chatbot Technology to Prevent HPV and HPV Associated Cancers for Ethnic Koreans Living in the U.S.

项目摘要/摘要 这个K23奖项的主要目标是为金敏进博士提供有组织的高级研究培训， 受保护的时间和改善健康差距、促进健康、预防疾病、 以及利用技术改善健康并接触到服务不足、资源不足的人口的创新。 候选人：金博士是一位跨文化的护士科学家，致力于研究健康差距，使用叙事或 “讲故事”的方法，以捕捉不同的人和社区的声音。她的长期目标 是设计和实施可持续的疾病预防计划，利用理论上- 以减少健康差距和促进健康公平为基础的、具有文化包容性和个人相关性的， 改善预防保健行为和结果，并接触到服务不足的高需求人群。金博士的 短期目标是利用人工智能(AI)聊天机器人进行讲故事干预，以促进 及时、有效和持续的激励接种疫苗，以预防HPV相关感染和癌症。 研究：人乳头瘤病毒(HPV)感染是一种性传播感染，四分之三的新感染病例 发生在15至24岁的个体中。尽管HPV疫苗在预防HPV相关疾病方面是安全有效的 感染和癌症，我们的初步研究表明，只有五分之一的说英语的大学学历的人 美国东北部18至26岁的韩裔美国妇女接种过HPV疫苗(19%)。金博士的 利用AI聊天机器人技术(K-Talk)的讲故事视频干预提供了以用户为中心的 促进18-26岁韩裔美国人HPV疫苗接种行为的经验。这项研究旨在1) 调整和改进之前开发的K-Talk和2)进行基于多阶段优化策略的试点 评估K-Talk的可行性、可接受性和初步疗效的试验。拟议的研究评估了 通过获得HPV疫苗接种卡的照片文件，获得主要结果(HPV疫苗接种率)。这 学习有很大的机会接触到服务不足、难以接触到的韩裔美国人和其他少数族裔。 K-Talk是一种很有前途的干预措施，可以促进HPV疫苗接种作为癌症预防的一种手段。 指导/培训：借助跨学科指导团队的专业知识和来自内部和 在辛辛那提之外，金博士将在五个领域实现她指定的研究和职业目标 她通过这个奖项进行的研究项目。这些领域是：使用状态设计干预研究 最先进的研究设计、基于mHealth和聊天机器人的技术，以改善健康沟通和 传播干预措施，进行和管理临床试验和实用试验，高级 临床试验数据的统计方法以及沟通和领导能力。拟议的研究 培训将使金博士能够独立进行未来的务实试验(R01)，评估 K-Talk干预在这一提议中试行。

PROJECT SUMMARY/ABSTRACT The primary goal of this K23 award is to provide Dr. Minjin Kim with the structured advanced research training, protected time, and mentoring necessary for improving health disparities, health promotion, disease prevention, and innovation using technology to improve health and to reach underserved, under-resourced populations. Candidate: Dr. Kim is a transcultural nurse scientist dedicated to health disparities research using a narrative or “storytelling” approach to capture the voices of a diverse range of people and communities. Her long-term goal is to design and implement sustainable disease prevention programs leveraging technologies that are theory- based, culturally inclusive, and personally relevant to reduce health disparities and promote health equity, improve preventive health behaviors and outcomes, and reach underserved, high-need populations. Dr. Kim’s short-term goal is to employ storytelling interventions leveraging artificial intelligence (AI) chatbots that facilitate timely, effective, and sustained motivation for vaccination to prevent HPV-related infections and cancers. Research: Human papillomavirus (HPV) infection is a sexually transmitted infection with 3 out of 4 new infections occurring in individuals aged 15 to 24. Although HPV vaccine is safe and effective at preventing HPV-related infections and cancers, our preliminary study has shown that only 1 in 5 English-speaking, college-educated Korean American women aged 18 to 26 in the Northeast U.S. had received the HPV vaccine (19%). Dr. Kim’s storytelling video-based intervention leveraging AI chatbot technology (K-Talk) delivers a user-centered experience to promote HPV vaccination behavior among Korean Americans aged 18 to 26. The study aims to 1) adapt and refine the previously developed K-Talk and 2) conduct a pilot Multiphase Optimization Strategy-based trial to assess feasibility, acceptability, and preliminary efficacy of K-Talk. The proposed study assesses the primary outcome (HPV vaccine uptake) by obtaining photo documentation of an HPV vaccination card. This study has a substantial opportunity to reach underserved, hard-to-reach Korean Americans and other minorities. K-Talk is a promising intervention to promote HPV vaccination as a means of cancer prevention. Mentoring/Training: With the expertise of the transdisciplinary mentoring team and consultants from inside and outside of Cincinnati, Dr. Kim will achieve her appointed research and career goals in five domains to advance her program of research through this award. These domains are: designing intervention studies using state-of- the-art research design, mHealth and chatbot-based technologies to improve health communication and dissemination of the interventions, conducting and managing clinical trials and pragmatic trials, advanced statistical methods for clinical trials data as well as communication and leadership skills. The proposed research and training will enable Dr. Kim to independently conduct a future pragmatic trial (R01) that evaluates efficacy of the K-Talk intervention piloted in this proposal.